Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective.
Diarmuid CoughlanOluwatomi ArisaKatie H ThomsonGe YuFiona PearsonAshleigh KernohanSonia Garcia Gonzalez-MoralSheila A WallaceStephen RicePublished in: PharmacoEconomics (2023)